News Sentiment

MYGN sentiment intelligence

Myriad Genetics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 4.54 Week of 19 Jun 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+4.8% over one week, +18.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 4.8% Price confirming higher
Trend fit Trend inactive 18.8% over four weeks
Fair value -67.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 29
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 10
TradingKey 4
simplywall.st 3
IndexBox 2
Yahoo! Finance Canada 1
MarketBeat 1
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 9
Balance sheet 4
Capital return 1
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
TradingKey Direct company coverage

Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Myriad Genetics Inc (MYGN) stock, focusing on its historical dividend payouts and stock split events. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:11
Source
TradingKey
TradingKey Direct company coverage

Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Myriad Genetics Inc (MYGN) as of April 6, covering analysis by business segment and geographical region. The company's main revenue streams are Hereditary Cancer, Prenatal, Pharmacogenomics, and Tumor Profiling, with Heredita

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:11
Source
TradingKey
TradingKey Direct company coverage

Myriad Genetics Inc (MYGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Myriad Genetics Inc (MYGN), highlighting its current earnings forecast score of 5.82, ranking it 184 out of 203 in its industry. Analysts have set an average price target of $8.00 for MY

Tone
Positive 60/100
Event
Earnings
Published
17 Jun 2026 02:09
Source
TradingKey
TradingKey Direct company coverage

Myriad Genetics Inc (MYGN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Myriad Genetics Inc (MYGN) as of June 16, 2026. The company's valuation score is 8.29, ranking it 98th in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.99, which is noted as being below its recent high and

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 09:09
Source
TradingKey
Stock Titan Direct company coverage

Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan

Myriad Genetics CEO Samraat S. Raha acquired 3,542 shares of common stock on June 11, 2026, through the company's Amended and Restated 2012 Employee Stock Purchase Plan at $3.936 per share. This transaction increases his direct holdings to 1,068,083 shares and is considered a rou

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan

Myriad Genetics Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock through the company's Employee Stock Purchase Plan at $3.936 per share. This transaction, exempt under Rule 16b-3(d) and Rule 16b-3(c), increased his direct holdings to 573,363 shares

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 22:10
Source
Stock Titan
Yahoo! Finance Canada Direct company coverage

Should You Add Myriad Genetics Stock to Your Portfolio Right Now?

Myriad Genetics (MYGN) is positioned for growth due to new product launches, particularly in oncology testing, and a sound solvency profile, despite foreign exchange headwinds. The company's focus on germline and tumor testing, alongside FDA approvals and upcoming AI-enhanced tes

Tone
Positive 67/100
Event
Market update
Published
12 Jun 2026 22:09
Source
Yahoo! Finance Canada
MarketBeat Direct company coverage

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts

Myriad Genetics (NASDAQ:MYGN) has received an average "Hold" rating from six analysts, with a consensus 12-month price target of $6.50. The company recently reported quarterly earnings that missed estimates, with an EPS of -$0.09 and revenue of $200.4 million, despite a 2.3% year

Tone
Neutral 50/100
Event
Earnings
Published
10 Jun 2026 19:09
Source
MarketBeat
Stock Titan Direct company coverage

Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan

Myriad Genetics Inc. director Rashmi Kumar sold 15,000 shares of common stock on June 8, 2026, at a weighted average price of $4.4562 per share, totaling $66,843. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Kumar directly owns

Tone
Negative 35/100
Event
Market update
Published
09 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

[144] MYRIAD GENETICS INC SEC Filing

This SEC filing details a Form 144 Notice of Proposed Sale of Securities for MYRIAD GENETICS INC (MYGN). The filing indicates an intent to sell 15,000 shares of common stock with an aggregate market value of $68,850.00, acquired via restricted stock vesting. The proposed sale dat

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 15:39
Source
Stock Titan
Stock Titan Direct company coverage

Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis

Myriad Genetics (MYGN) director Mark Steven Davis was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan, bringing his total direct holdings to 106,665 common shares. These RSUs were granted at no purchase price and will vest on the e

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 05:10
Source
Stock Titan
Stock Titan Direct company coverage

Myriad Genetics (MYGN) director awarded 59,701 restricted stock units

Myriad Genetics (MYGN) director Lee Nisley Newcomer was granted 59,701 restricted stock units, as reported in a recent Form 4 SEC filing. These units, awarded at no purchase price under the company’s 2026 Equity Incentive Plan, will vest upon the earlier of the first anniversary

Tone
Positive 61/100
Event
Market update
Published
06 Jun 2026 04:40
Source
Stock Titan
Stock Titan Direct company coverage

Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units

Myriad Genetics director Colleen F. Reitan was granted 59,701 restricted stock units (RSUs) under the company's 2026 Employee, Director and Consultant Equity Incentive Plan. This equity award, which is compensation-related rather than a stock purchase, increases her direct holdin

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] MYRIAD GENETICS INC Insider Trading Activity

Myriad Genetics Inc. director S. Louise Phanstiel was granted 59,701 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan at no cash cost. These RSUs will vest upon the earlier of one year from the grant date or the next annual stockholders' meeting. Follo

Tone
Neutral 50/100
Event
Balance sheet
Published
05 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award

Myriad Genetics (NASDAQ: MYGN) director Rashmi Kumar was granted 59,701 restricted stock units (RSUs) as an equity award, bringing her direct holdings to 186,889 shares. These RSUs were granted at no cash cost under the company's 2026 Employee, Director and Consultant Equity Ince

Tone
Neutral 50/100
Event
Balance sheet
Published
05 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant

Myriad Genetics (MYGN) Director Heinrich Dreismann was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan. These RSUs, awarded at no cash cost, will vest upon the earlier of one year from the grant date or the next annual stockholder

Tone
Neutral 50/100
Event
Balance sheet
Published
05 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro

Myriad Genetics (MYGN) director Paul Bisaro has been granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Employee, Director and Consultant Equity Incentive Plan. These RSUs, which have no purchase price, will vest on the earlier of one year from the grant d

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:38
Source
Stock Titan
Market source Direct company coverage

Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?

Myriad Genetics (MYGN) shares have risen 7.1% since its last earnings report, outperforming the S&P 500. Despite missing Q1 earnings estimates with an adjusted loss of 9 cents per share and a revenue miss, the company's Cancer Care Continuum and Mental Health businesses showed gr

Tone
Neutral 50/100
Event
Earnings
Published
05 Jun 2026 04:38
Source
Market source
Stock Titan Direct company coverage

Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans

Myriad Genetics (NASDAQ: MYGN) held its 2026 Annual Meeting of Stockholders, where shareholders approved significant expansions to the company's equity and stock purchase plans. This included an amendment to the 2012 Employee Stock Purchase Plan adding 4,000,000 shares and the ad

Tone
Positive 64/100
Event
Market update
Published
04 Jun 2026 20:09
Source
Stock Titan
GuruFocus Direct company coverage

Myriad Genetics Inc Annual Shareholders Meeting Transcript

This article provides the transcript for the 2026 Annual Shareholders Meeting of Myriad Genetics Inc. The meeting was called to order by Independent Chairman of the Board, S. Louise Phanstiel, at 8:00 AM Mountain Time, and an agenda for the meeting was made available on the compa

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 14:09
Source
GuruFocus
GlobeNewswire Direct company coverage

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Myriad Genetics, a leader in molecular diagnostic testing, has appointed Raj Jampa as its new Chief Technology Officer, effective June 1, 2026. Jampa will be responsible for technology strategy and execution, focusing on leveraging AI to enhance efficiency and customer experience

Tone
Positive 71/100
Event
Market update
Published
03 Jun 2026 04:09
Source
GlobeNewswire
Stock Titan Direct company coverage

Myriad Genetics (MYGN) CTO Raj Jampa receives 251,889 restricted stock units

Myriad Genetics' CTO, Raj Jampa, has been granted 251,889 restricted stock units (RSUs) as part of an equity compensation package. This award, which has no cash purchase price, vests in four equal annual installments starting one year from the grant date, aligning his compensatio

Tone
Neutral 50/100
Event
Balance sheet
Published
02 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Myriad Genetics (MYGN) CTO Raj Jampa files initial Form 3 insider report

Raj Jampa, Chief Technology Officer of Myriad Genetics (MYGN), has filed an initial Form 3 insider report. This filing establishes him as an insider for future reporting purposes but does not record any stock or option transactions, indicating a neutral impact on the company's st

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 20:10
Source
Stock Titan
Moomoo Direct company coverage

Press Release: Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Myriad Genetics has announced the appointment of Raj Jampa as its new Chief Technology Officer (CTO). Jampa will be responsible for leading the company's technology strategy, including software development and bioinformatics infrastructure. This strategic hire aims to enhance Myr

Tone
Positive 71/100
Event
Market update
Published
02 Jun 2026 15:10
Source
Moomoo
Investing.com Direct company coverage

Myriad Genetics names Raj Jampa as chief technology officer

Myriad Genetics, Inc. has appointed Raj Jampa as its new chief technology officer, effective Monday. Jampa will be responsible for leading the company's technology strategy, modernizing infrastructure, and scaling AI capabilities. His appointment is expected to help the molecular

Tone
Positive 67/100
Event
Market update
Published
02 Jun 2026 13:40
Source
Investing.com
Stocktwits Direct company coverage

Myriad Genetics, Inc. (MYGN) News, Articles, Events & Latest Updates

This page provides the latest news and updates for Myriad Genetics, Inc. (MYGN), including stock performance, financial fundamentals, and recent articles. Key topics covered include the company's Q1 2026 earnings, upcoming product launches like the Prolaris + AI Test, analyst rat

Tone
Positive 64/100
Event
Earnings
Published
29 May 2026 15:10
Source
Stocktwits